Lupin Acquires European Eye Care Firm VISUfarma

Lupin Limited, the global pharmaceutical powerhouse headquartered in Mumbai, has finalized its strategic acquisition of VISUfarma B.V., a prominent European specialty pharmaceutical firm concentrating on ophthalmology. This move, orchestrated with GHO Capital Partners LLP as the seller, significantly amplifies Lupin’s footprint in the European market and deepens its commitment to the high-growth eye care sector.

The integration of VISUfarma injects a robust portfolio of over 60 branded products into Lupin's offerings, addressing critical areas such as dry eye, glaucoma, and retinal health, alongside specialty nutraceuticals. This expansion is particularly timely, given the increasing global demand for advanced ophthalmic solutions. Factors like an aging demographic and the rising incidence of diabetes-related eye conditions are driving substantial market growth, with the global ophthalmology market projected to reach over $40 billion by 2027, exhibiting a compound annual growth rate of approximately 5%.

VISUfarma brings not only a comprehensive product range but also a well-established commercial infrastructure across key European territories, including Italy, the UK, Spain, Germany, and France. The company's seasoned team possesses deep-rooted expertise in ophthalmology, fostering trusted relationships and invaluable local market intelligence. This established presence is expected to accelerate Lupin's specialty franchise development and enhance its ability to serve a wider patient base.

Vinita Gupta, CEO of Lupin, highlighted the acquisition's immediate accretive nature and its role in expanding the company's European reach. "This strategic acquisition will also expand our presence across Europe and accelerate the build-out of our specialty franchise," Gupta stated, emphasizing the value of VISUfarma's differentiated portfolio and established commercial network. The deal underscores Lupin's ambition to become a leader in specialized therapeutic areas.

VISUfarma, founded in 2016 through the amalgamation of Italy's Visufarma SpA and the European commercial operations of Nicox SA, generated approximately €53 million in revenue in 2025. Its acquisition by GHO Capital in the same year marked a significant step in its growth trajectory. Now, under Lupin's stewardship, the company is poised for further expansion, leveraging global resources and strategic direction.

This transaction positions Lupin to capitalize on the evolving dynamics within the ophthalmology market. The company's enhanced capabilities, combined with VISUfarma's specialized expertise and market penetration, are expected to drive significant value creation and improve patient outcomes in eye care across Europe and potentially beyond. The integration is anticipated to yield substantial synergies, reinforcing Lupin's competitive standing in the pharmaceutical sector.